Macu'ta: Metacognitive Training as a Serious Game

Sponsor
Christina Andreou (Other)
Overall Status
Recruiting
CT.gov ID
NCT04631939
Collaborator
(none)
36
2
2
20
18
0.9

Study Details

Study Description

Brief Summary

The project aims to evaluate the efficacy of a therapeutic video game that incorporates elements from metacognitive training on delusions and jumping-to-conclusions in patients with psychotic disorders.

Condition or Disease Intervention/Treatment Phase
  • Device: Metacognitive training game
  • Device: Control games
N/A

Detailed Description

The study is an international, multicenter study and is being conducted in Switzerland (University of Basel) as well as in Germany (University of Lübeck). A total of 36 participants will be included. The estimated duration of the study is 15 months. All participants play a video game from the genre "Third Person Adventure". A character is navigated through a fantasy world using a keyboard and mouse. In the fantasy world, "stations" in the form of glowing gems are sought where players have to solve different tasks.

Participants are randomized to receive either the therapeutic video game with metacognitive training content or another video game with attention and memory tasks ("control intervention"). The control intervention does not include metacognitive tasks. Metacognitive training is an approach for the treatment of psychotic disorders, particularly delusions. The focus of metacognitive training is on thought distortions (so-called "cognitive biases") that are more pronounced in people with psychosis. The control intervention includes easily understandable, playful tasks. The intervention will take 4 appointments within 2 weeks.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
36 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Metacognitive Training as a Serious Game: A New Approach for the Treatment of Delusions
Actual Study Start Date :
Jun 1, 2021
Anticipated Primary Completion Date :
Feb 1, 2023
Anticipated Study Completion Date :
Feb 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: study intervention

The intervention consists of a puzzle adventure game, in which players have to explore the fantasy world "Macu'ta". The puzzles are based on Metacognitive Training for Psychosis (MCT), an intervention using playful, entertaining exercises to increase awareness of reasoning biases in patients and 'sow the seeds of doubt' through corrective ('aha!') experiences. The tasks will address reasoning biases associated with the emergence and maintenance of delusions.

Device: Metacognitive training game
In the fantasy world "Macu'ta", players explore the world by walking around with an avatar in order to find the puzzles and proceed in the game. The intervention consists of 4 different puzzles. Unbeknownst to the player, the first pieces of evidence of each puzzle are often misleading, i.e. indicate the wrong solution, such that hasty decisions are punished. Players receive immediate feedback and are shown the correct response after submitting their solution, as well as explicit cues that educate them on the value of making adequately informed decisions. The order of the puzzles is fixed for each player, but different per session.

Sham Comparator: control intervention

The control intervention consists of a puzzles focused exclusively on dexterity and accuracy.

Device: Control games
In the fantasy world "Macu'ta", players explore the world by walking around with an avatar in order to find the puzzles and proceed in the game. The control intervention consists of 4 different puzzle games requiring exclusively dexterity and accuracy (i.e., not including any metacognitive elements). The order of the puzzles is fixed for each player, but different per session.

Outcome Measures

Primary Outcome Measures

  1. Change of delusion severity [Change from pre- to post-intervention (4 weeks)]

    Item P1 of the Positive and Negative Syndrome Scale (PANSS). Min score = 1, max score = 7, where lower scores indicate better outcome.

Secondary Outcome Measures

  1. Change of total PANSS Score [Change from pre- to post-intervention (4 weeks)]

    Total score on the Positive and Negative Syndrome Scale. Lower scores indicate better outcome.

  2. Change of delusional conviction [Change from pre- to post-intervention (4 weeks)]

    Total score on the Psychotic Symptom Rating Scales, delusion part (PSYRATS). Lower scores indicate better outcome.

  3. Fish Task: change of number of draws to decision [Change from pre- to post-intervention (4 weeks)]

    Number of draws to decision, assessed with the 'Fish task'

  4. Fish Task: change of probability threshold to decision [Change from pre- to post-intervention (4 weeks)]

    Probability threshold to decision, assessed with the 'Fish task'

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 40 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • aged between 18 and 40

  • diagnosis of a psychotic disorder and current delusions or a history of delusions

Exclusion Criteria:
  • Language skills insufficient for assessments

  • IQ < 70

  • Secondary psychotic disorders that are clearly induced by general medical conditions or substance use.

  • Previous participation in meta-cognitive training for psychosis

Contacts and Locations

Locations

Site City State Country Postal Code
1 Center for Integrative Psychiatry Lübeck Lübeck Schleswig-Holstein Germany 23538
2 University Psychiatric Clinics Basel Basel Basel-Stadt Switzerland 4055

Sponsors and Collaborators

  • Christina Andreou

Investigators

  • Principal Investigator: Christina Andreou, PD Dr., University of Basel
  • Principal Investigator: Stefan Borgwardt, Prof. Dr., University of Luebeck

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Christina Andreou, Principal Investigator, University of Basel
ClinicalTrials.gov Identifier:
NCT04631939
Other Study ID Numbers:
  • 2020-02291
First Posted:
Nov 17, 2020
Last Update Posted:
Feb 21, 2022
Last Verified:
Feb 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Christina Andreou, Principal Investigator, University of Basel
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 21, 2022